Tute Genomics closes additional Series A1 funding

Tute Genomics

Tute Genomics has closed its Series A1 round of funding, raising more than $3.9 million from a “strategic group of investors,” including Intermountain Healthcare, an integrated network of 22 hospitals and 185 physician clinics. Other major investors include Healthbox and China-based Tencent, which is one of the largest Internet companies in the world. As part of the deal, Nina Nashif, founder and CEO of Healthbox, will be joining the Tute Genomics Board on behalf of Intermountain Healthcare.

The company is a leader in cloud-based analytics, interpretation, and reporting for clinical sequencing, with the goal to bring technology for genome-guided precision medicine to the masses.

“Tute Genomics has worked tirelessly to make clinical interpretation and reporting of genomic data accessible to healthcare providers, and international investors have taken notice,” stated Kai Wang, PhD, President and Chairman of Tute Genomics. “Previous investors in this series include Peak Ventures and UK-based Eurovestech. Together with our partners, we have the power to transform healthcare and improve the lives of millions of people.”

Tute envisions a future where genome sequencing is part of routine clinical care, with genomic data integrated into medical records where it is most useful and actionable, giving doctors and patients alike access to genomic information at their fingertips. Genomics is changing healthcare as we know it, and with this new support from strategic investment partners, Tute is well poised to help shape the future of medicine: unlocking the genome, personalizing treatment, and accelerating discovery.